Eric Sagonowsky

Eric Sagonowsky is an editor with FiercePharma and FierceVaccines. He joined the Fierce staff in 2014 and covers topics like drug pricing, biosimilars and product liability litigation.

Biography:  https://www.fiercebiotech.com/author/eric-sagonowsky

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

95%

Examples:

  • In the article 'Sanofi, AZ's infant RSV med Beyfortus in short supply as RSV season brings surging demand', the author tends to focus heavily on the pharmaceutical companies' perspective, with less emphasis on the impact on patients.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

CDC Recommends New RSV Vaccine Amid Shortage Concerns

Broke On: Tuesday, 24 October 2023 The CDC has updated its guidelines to recommend a new RSV vaccine for all infants under six months and pregnant women. The vaccine, Beyfortus, is facing a shortage due to manufacturing issues and increased demand.

AstraZeneca Seeks FDA Approval for Self-Administration of FluMist Vaccine

Broke On: Tuesday, 24 October 2023 AstraZeneca has submitted a request to the FDA to allow adults to self-administer its annual flu vaccine, FluMist. The company's request is based on data from a study that demonstrated the safety and efficacy of self-administration of FluMist.